83 related articles for article (PubMed ID: 34176174)
1. Metabolic reprogramming and immune regulation in viral diseases.
Ganesh GV; Mohanram RK
Rev Med Virol; 2022 Mar; 32(2):e2268. PubMed ID: 34176174
[TBL] [Abstract][Full Text] [Related]
2. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
Elife; 2020 May; 9():. PubMed ID: 32452762
[TBL] [Abstract][Full Text] [Related]
4. Management of epigenomic networks entailed in coronavirus infections and COVID-19.
El Baba R; Herbein G
Clin Epigenetics; 2020 Aug; 12(1):118. PubMed ID: 32758273
[TBL] [Abstract][Full Text] [Related]
5. Could metabolomics drive the fate of COVID-19 pandemic? A narrative review on lights and shadows.
Mussap M; Fanos V
Clin Chem Lab Med; 2021 Nov; 59(12):1891-1905. PubMed ID: 34332518
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
Kim CH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
[TBL] [Abstract][Full Text] [Related]
7. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
[TBL] [Abstract][Full Text] [Related]
8. Unravelling host-pathogen interactions: ceRNA network in SARS-CoV-2 infection (COVID-19).
Arora S; Singh P; Dohare R; Jha R; Ali Syed M
Gene; 2020 Dec; 762():145057. PubMed ID: 32805314
[TBL] [Abstract][Full Text] [Related]
9. Role of Multiomics Data to Understand Host-Pathogen Interactions in COVID-19 Pathogenesis.
Aggarwal S; Acharjee A; Mukherjee A; Baker MS; Srivastava S
J Proteome Res; 2021 Feb; 20(2):1107-1132. PubMed ID: 33426872
[TBL] [Abstract][Full Text] [Related]
10. [Interaction between SARS-CoV-2 and Host Innate Immunity].
Duan XQ; Xie H; Chen LM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):1-6. PubMed ID: 35048592
[TBL] [Abstract][Full Text] [Related]
11. A consideration of publication-derived immune-related associations in Coronavirus and related lung damaging diseases.
Geifman N; Whetton AD
J Transl Med; 2020 Aug; 18(1):297. PubMed ID: 32746922
[TBL] [Abstract][Full Text] [Related]
12. The SARS-CoV-2 Coronavirus and the COVID-19 Outbreak.
Lauxmann MA; Santucci NE; Autrán-Gómez AM
Int Braz J Urol; 2020 Jul; 46(suppl.1):6-18. PubMed ID: 32549071
[TBL] [Abstract][Full Text] [Related]
13. Metabolomics Signatures of SARS-CoV-2 Infection.
Arjmand B; Alavi-Moghadam S; Parhizkar-Roudsari P; Rezaei-Tavirani M; Tayanloo-Beik A; Goodarzi P; Mehrdad N; Mohamadi-Jahani F; Larijani B
Adv Exp Med Biol; 2022; 1376():45-59. PubMed ID: 34735713
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions.
Wakabayashi M; Pawankar R; Narazaki H; Ueda T; Itabashi T
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):1-7. PubMed ID: 33186186
[TBL] [Abstract][Full Text] [Related]
15. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.
Deng X; Buckley AC; Pillatzki A; Lager KM; Faaberg KS; Baker SC
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554697
[TBL] [Abstract][Full Text] [Related]
16. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice.
Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A
mBio; 2021 Apr; 12(2):. PubMed ID: 33879586
[TBL] [Abstract][Full Text] [Related]
17. [SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].
Erensoy S
Mikrobiyol Bul; 2020 Jul; 54(3):497-509. PubMed ID: 32755524
[TBL] [Abstract][Full Text] [Related]
18. Controlling the Burden of COVID-19 by Manipulating Host Metabolism.
Miller L; Berber E; Sumbria D; Rouse BT
Viral Immunol; 2022; 35(1):24-32. PubMed ID: 34905407
[TBL] [Abstract][Full Text] [Related]
19. Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses.
Sperk M; van Domselaar R; Rodriguez JE; Mikaeloff F; Sá Vinhas B; Saccon E; Sönnerborg A; Singh K; Gupta S; Végvári Á; Neogi U
J Proteome Res; 2020 Nov; 19(11):4259-4274. PubMed ID: 33095583
[TBL] [Abstract][Full Text] [Related]
20. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
